Sermo, Bloomberg partner on service for healthcare investors

Share this article:
Sermo has teamed up with Bloomberg to develop a groundbreaking forum that gives healthcare investors instant access to medical information and the opinions of its community of physicians—a venture that Sermo CEO Daniel Palestrant, MD, believes “has the potential to reward with greater investment those products and services that are most effective, rather than those that are well-promoted.”

The Healthcare Exchange, demonstrated for the first time to a select audience of industry leaders last night in San Francisco, gives users direct access to the observations and insights of Sermo's 90,000-strong physician community through the Bloomberg Professional Service. With one click, 280,000-plus analysts and investors can gain instant access to what Palestrant described as “the front-lines of medicine,” giving users “actionable intelligence about therapies and devices” on which to base investing decisions—and effectively offering early intelligence of market-changing events in healthcare.

Investors and analysts will be able to pose questions to physicians to gauge opinion and reactions to potentially market-changing information, such as company statements about the efficacy of therapies or media stories about adverse events.

Palestrant told the invitation-only audience that the Healthcare Exchange will “tear down” barriers to information. “For physicians, this provides a voice beyond the bound of their community,” he said. “For investors, it is a disruptive technology that leads to more transparent information and better investment decisions.”

The new service will become a feature of the Bloomberg function BDRUG, which provides daily-updated information on every drug marketed in the US, from clinical trials results to prescription data, and will be available as part of the Bloomberg Professional service.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.